Navigation Links
ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
Date:4/2/2009

RANCHO CORDOVA, Calif., April 2 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that its devices will be the subject of several scientific abstracts to be presented at the International Stem Cell Therapy (ISCT) 2009 Annual Meeting in San Diego, May 3-6.

The abstracts will cover the efficacy of the Company's BioArchive(R) System, MarrowXpress(TM) (MXP(TM)) and Res-Q(TM) devices in the processing of stem cells from cord blood and bone marrow. Additional abstracts will address the impact of sterilization practices on stem cell processing, and findings regarding the collection of equine stem cells. The Company will also be demonstrating its products at booth #200.

"We are delighted to have the opportunity to contribute to this leading stem cell industry conference. We believe this forum provides us the opportunity for the industry to be aware of the value of our devices in the collection and storage of stem cells from cord blood and bone marrow, as well as our ability to bring innovation to the market through devices such as the MXP and Res-Q," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.

The abstracts to be presented at the ISCT include:

  • Findings from a company study designed to evaluate the efficiency of stem cell recovery from bone marrow following processing with the MXP and cryopreservation with the BioArchive. This study was conducted prior to the commercial launch of the MXP in late 2008. The data demonstrated nearly one hundred percent stem cell recovery and that the MXP can be successfully used to volume reduce and harvest stem cells from human bone marrow in a functionally closed system.
  • Results from a company study usin
    '/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThermoGenesis Says FDA Concurs with Plan for Previously Announced AXP(TM) Bagset Recall
2. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
3. ThermoGenesis Presentation at Rodman & Renshaw Conference
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
5. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
6. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
7. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
8. ThermoGenesis Names Tiffany Olson to Board of Directors
9. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... "Company"), a diversified life sciences company, today announced that ... authorized shares of common stock of the Company from ... held on July 27, 2015 at the Law Offices ... Meeting").   At the Special Meeting, there were 480,655,929 shares ...
(Date:7/28/2015)... MORRISTOWN, N.J. , July 28, 2015 /PRNewswire/ ... its second Phase 1 clinical trial with MMI-0100, ... that is being developed for pulmonary disorders characterized ... the United Kingdom , is ... study further evaluating the safety and tolerability of ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 /PRNewswire/ ... announced its financial results for the second quarter ... grew nearly 300% as compared to the second ... launched," said Roger Jeffs, Ph.D., United Therapeutics, President ... sales was due to an increase in the ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... Anca Copaescu, then a second-year MBA in the University of ... Burrill Technology Business Plan Competition, she knew she wanted to ... though the money definitely got her attention. It was the ... of her deepest dreams. "Even as a child growing up ...
... , ,Its a strategy, process and technology ... across the entire spectrum of local, state, national, and ... life sciences and information technology. We can help our ... tourism, manufacturing, and agriculture to operate in real- time. ...
... most common question Im asked is, Why wont angels invest in ... 90+% of the entrepreneurs asking this question. The irony is that ... though it isnt the answer they are expecting. The less ... is serious and problematic. , , Angels vs. angel networks ...
Cached Biology Technology:Romanian Student Leverages Burrill Competition to Accomplish Her Dream 2Romanian Student Leverages Burrill Competition to Accomplish Her Dream 3Real-Time Economy: Part 2 2What Angel Networks Want 2What Angel Networks Want 3What Angel Networks Want 4What Angel Networks Want 5
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... discovered the presence of functional ion channels in human ... electrical wires and permit ESCs, versatile cells that possess ... the body, to conduct and pass along electric currents. ... channels in implanted cells, derived from stem cells, they ...
... pathogenic fungi as model systems for understanding fungal diseases, ... offers insight into how carbon dioxide (CO2) governs the ... different environments and invade the human body, and they ... utilize evolutionarily conserved enzymes to control the growth and ...
... medieval Europe ?to fade from the scene? By the ... The reason seems to be, say researchers at the ... a far more deadly disease, overtook leprosy, killing millions ... examination of DNA from human remains from the ancient ...
Cached Biology News:Stem cells' electric abilities might help their safe clinical use 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3Once-dreaded leprosy 'replaced' by tuberculosis, say researchers 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Asb-2 (Ankyrin repeat and SOCS box-containing protein) ... peptides containing amino acids 75-93 and 348-368 ... (Imgenex Catalog No. 40149) can be used ... react with mouse and rat Asb-2, based ...
... Monoclonal Antibody, Unconjugated Applications: ... ICC: Use at an assay dependent dilution. WB: ... ug/ml, this concentration is determined using a whole ... kDa. Not tested in other applications. Optimal ...
Biology Products: